- Ticker
- ACON
- Price
- 0.60
- Stock movement down
- -0.15 (-20.00%)
- Company name
- Aclarion Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Health Information Services
- Market cap
- 4.69M
- Ent value
- 3.21M
- Price/Sales
- 94.04
- Price/Book
- 1.60
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -8.41%
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2023-02-03
DIVIDENDS
ACON does not pay dividends
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 94.04 |
| Price to Book | 1.60 |
| EV to Sales | 64.23 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 7.82M |
| EPS (TTM) | -1.20 |
| FCF per share (TTM) | -0.63 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 49.90K |
| Gross profit (TTM) | -14.33K |
| Operating income (TTM) | -5.84M |
| Net income (TTM) | -9.41M |
| EPS (TTM) | -1.20 |
| EPS (1y forward) | -0.42 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -28.71% |
| Operating margin (TTM) | -11703.93% |
| Profit margin (TTM) | -18863.43% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 2.66M |
| Net receivables | 25.50K |
| Total current assets | 2.88M |
| Goodwill | 0.00 |
| Intangible assets | 1.22M |
| Property, plant and equipment | 0.00 |
| Total assets | 4.10M |
| Accounts payable | 718.28K |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 1.17M |
| Total liabilities | 1.17M |
| Shareholder's equity | 2.93M |
| Net tangible assets | 1.72M |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -4.75M |
| Capital expenditures (TTM) | 188.34K |
| Free cash flow (TTM) | -4.94M |
| Dividends paid (TTM) | 415.52K |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -320.96% |
| Return on Assets | -229.52% |
| Return on Invested Capital | -320.96% |
| Cash Return on Invested Capital | -168.52% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.71 |
| Daily high | 0.75 |
| Daily low | 0.60 |
| Daily Volume | 29K |
| All-time high | 2.72 |
| 1y analyst estimate | 3.00 |
| Beta | - |
| EPS (TTM) | -1.20 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 1 Mar 2023 |
Downside potential
Loading...
Downside potential data
| ACON | S&P500 | |
| Current price drop from All-time high | -77.94% | -13.68% |
| Highest price drop | -85.66% | -56.47% |
| Date of highest drop | 27 Dec 2022 | 9 Mar 2009 |
| Avg drop from high | -63.21% | -11.49% |
| Avg time to new high | 199 days | 13 days |
| Max time to new high | 198 days | 1805 days |
COMPANY DETAILS
Marketcap
4.69M
Marketcap category
Small-cap
Description
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.
Employees
3
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Director of Endoscopic Spine Surgery at the University of Miami Broomfield, CO, Jan. 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW...
January 31, 2023
Broomfield, CO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers ...
January 17, 2023
Broomfield, Colorado--(Newsfile Corp. - January 17, 2023) - Aclarion, Inc., (NASDAQ: ACON) (NASDAQ: ACONW) ("Aclarion" or the "Company"), a healthcare technology company that is leveraging biomarkers ...
January 17, 2023
Broomfield, CO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers...
December 22, 2022
Development of this program supports Aclarion’s commitment to lead with strong clinical evidence and engage the payer community through key opinion leader advocacy. Broomfield, CO, Dec. 21, 2022 (GLOB...
December 21, 2022
Dr. Uribe is the fourth national KOL to join the Aclarion team this year. Development of this program supports Aclarion’s commitment to lead with strong clinical evidence and engage the payer communit...
December 19, 2022
Strengthens portfolio by addressing the anaerobic bacteria that can seed into the intervertebral disc, proliferate, and accelerate painful disc degeneration. Successful commercialization of IP holds t...
December 1, 2022
Aclarion ( NASDAQ:ACON ) Third Quarter 2022 Results Key Financial Results Net loss: US$1.63m (loss widened by 90% from...
November 16, 2022
/ Aclarion, Inc. (NASDAQ:ACON)(NASDAQ:ACONW) ("Aclarion" or the "Company"), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help phys...
October 25, 2022
Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians ...
October 24, 2022
Next page